| Literature DB >> 32158749 |
Santosh Yadav1, Ashwani Kumar Sharma1, Pradeep Kumar1.
Abstract
Self-assembly is the process of association of individual units of a material into highly arranged/ordered structures/patterns. It imparts unique properties to both inorganic and organic structures, so generated, via non-covalent interactions. Currently, self-assembled nanomaterials are finding a wide variety of applications in the area of nanotechnology, imaging techniques, biosensors, biomedical sciences, etc., due to its simplicity, spontaneity, scalability, versatility, and inexpensiveness. Self-assembly of amphiphiles into nanostructures (micelles, vesicles, and hydrogels) happens due to various physical interactions. Recent advancements in the area of drug delivery have opened up newer avenues to develop novel drug delivery systems (DDSs) and self-assembled nanostructures have shown their tremendous potential to be used as facile and efficient materials for this purpose. The main objective of the projected review is to provide readers a concise and straightforward knowledge of basic concepts of supramolecular self-assembly process and how these highly functionalized and efficient nanomaterials can be useful in biomedical applications. Approaches for the self-assembly have been discussed for the fabrication of nanostructures. Advantages and limitations of these systems along with the parameters that are to be taken into consideration while designing a therapeutic delivery vehicle have also been outlined. In this review, various macro- and small-molecule-based systems have been elaborated. Besides, a section on DNA nanostructures as intelligent materials for future applications is also included.Entities:
Keywords: amphiphilicity; drug delivery; nanostructures; polymers; self-assembly; small molecules
Year: 2020 PMID: 32158749 PMCID: PMC7051917 DOI: 10.3389/fbioe.2020.00127
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
FIGURE 1“Top-down” and “bottom-up” approaches of self-assembly.
FIGURE 2Atomic, molecular, colloidal self-assemblies based on size or nature of building units, and biological, interfacial on the basis of system where the self-assembly occurs. The length range is of structural units.
FIGURE 3Three classes of distinctive forces involved in self-assembly.
List of nanoengineered polymers for drug delivery applications (Felice et al., 2014; Bobo et al., 2016; Patra et al., 2018).
| LivatagTM | Poly(isohexyl-cyanoacrylate) | Doxorubicin/anthracycline (hepatocellular carcinoma) | Phase II |
| Lupron DepotTM | PLA | Leuprolid/peptidic (Prostate and breast cancer) | 1989 |
| EstrasorbTM | Lecithin | Estradiol/esteroide (Hot flushes during menopause) | 2003 |
| Risperdal constaTM | PLGA | Risperidone/dopamine antagonist (bipolar disorder Schizophrenia) | 2003 |
| AbraxaneTM | Albumin | Paclitaxel/anthracycline (Breast cancer) | 2005 |
| Genexol-PMTM | PEG–PLA | Paclitaxel/anthracycline (Breast cancer) | Phase II |
| AdagenTM | PEG | Adenosine deaminase/peptidic (Severe combined immunodeficiency) | 1990 |
| OncasparTM | PEG | Asparaginase/peptidic (Leukemia) | 1994 |
| PEG-intronTM | PEG | Interferon α2b/proteic (Chronic hepatitis C) | 2001 |
| CimziaTM | PEG | Interferon α2b/proteic (Chron’s disease) | 2008 |
| OmontysTM | PEG | Peginesatide acetate/peptidic (Anemia) | 2012 |
| XyotaxTM | Polyglumex | Paclitaxel/anthracycline (Lung cancer, ovarian cancer) | Phase III |
| PuricaseTM | PEG | Uricase/proteic (Hyperuricemia) | Phase III |
| MylotargTM | Anti-CD33 monoclonal antibody | Ozogamicin/calicheamicins (Leukemia) | 2000 |
| ZevalinTM | Anti-CD20 monoclonal antibody | Yttrium-90/radioactive material (Non-Hodgkin’s lymphoma) | 2002 |
| BexxarTM | Anti-CD20 monoclonal antibody | Iodine-131/radioactive material (Non-Hodgkin’s lymphoma) | 2003 |
| KadcylaTM | Anti-CD37 monoclonal antibody | Emtansine/maytansinoid (Breast cancer) | 2013 |
| Opaxio | Paclitaxel covalently linked to solid NPs of polyglutamate | Paclitaxel (Metastatic breast cancer) | 2012 |
| Cimzia | Pegylated antibody fragment | Certolizumab pegal (Crohn’s disease, rheumatoid arthritis, psoriatic arthritis, spondylitis) | 2008 |
| Plegridy | Pegylated IFN-B1 protein | Interferon B (Multiple sclerosis) | 2015 |
| Adynovate (Baxalta) | Pegylated factor VIII | FACTOR VIII (Hemophilia) | 2015 |
| Zilretta | Triamcinolone acetonide with a polylactic-co-glycolic acid matrix microsphere | Osteoarthritis of the knee | 2017 |
| Rebinyn | Coagulation factor IX GlycoPEGylated | Control and prevention of bleeding in perioperative setting for hemophilia B patients | 2017 |
List of nanoengineered liposomal therapeutic delivery systems either approved by FDA or in advanced clinical trials (Felice et al., 2014; Bulbake et al., 2017; Patra et al., 2018).
| DoxilTM | HSPC:cholesterol:PEG 2000-DSPE (56:39:5 molar ratio) | Doxorubicin/anthracycline (Various types of cancers) | 1995 |
| DaunoXomeTM | DSPC and cholesterol (2:1 molar ratio) | Daunorubicin/anthracycline (HIV) | 1996 |
| AmbisomeTM | HSPC:DSPG:cholesterol:(2:0.8:1 molar ratio) | Amphotericin B/polyene (Fungal infections) | 1997 |
| DepocytTM | DOPC, DPPG, cholesterol, and triolein | Cytarabin/nucleoside (Lymphomatous meningitis) | 1999 |
| VisudyneTM | Verteporphin:DMPC and EPG (1:8 molar ratio) | Verteporfin/benzoporphyrin (Macular degeneration) | 2000 |
| DepoDurTM | DOPC, DPPG, cholesterol, and triolein | Morphine/opiate (Severe pain) | 2004 |
| OctocogTM | Phospholipids | α Factor VIII/proteica (Hemophilia) | 2009 |
| MarqiboTM | SM:cholesterol (60:40 molar ratio) | Vincristine/alkaloidsulfate (Hodgkin lymphoma) | 2012 |
| MyocetTM | EPC:cholesterol (55:45 molar ratio) | Doxorubicin/anthracycline (Metastatic breast cancer) | Phase III/2000 |
| ThermodoxTM | Low phase transition temperature phospholipids | Doxorubicin/anthracycline (Metastatic malignant melanoma, liver cancer) | Phase III |
| OnivydeTM | DSPC:MPEG-2000:DSPE (3:2:0.015 molar ratio) | Irinotecan (Pancreatic cancer CRC, lung, glioma) | 2015 (approved for pancreatic cancer), Phase II, III trials for other cancers |
| Mepact | DOPS:POPC (3:7 molar ratio) | Mifamurtide (Non-metastaic osteosarcoma) | 2004 |
| Abelcet | DMPC:DMPG (7:3 molar ratio) | Amphotericin B (Invasive several fungal infections) | 1995 |
| Amphotec | Cholesteryl sulfate | Amphotericin B (Severe fungal infections) | 1996 |
| Exparel | DEPC, DPPG, cholesterol, tricaprylin | Pain managment | 2011 |
| Epaxal | DOPC:DOPE (75:25 molar ratio) | Hepatitis A | 1993 |
| Inflexal | DOPC:DOPE (75:25 molar ratio) | Influenza | 1997 |
| Vyxeos (CPX-351) | DSPC:DSPG:cholesterol (7:2:1 molar ratio) | Acute myeloid leukemia | 2017 |
FIGURE 4TEM images of (a) Boc-F-ΔF-Ahx-GA dipeptide, (b) FAE-loaded Boc-F-ΔF-Ahx-GA dipeptide, (c) Boc-F-ΔF-Ahx-Neomycin dipeptide, (d) Curcumin-loaded Boc-F-ΔF-Ahx-Neomycin dipeptide, (e) Boc-P-F-G-OMe tripeptide and (f) Curcumin-loaded Boc-P-F-G-OMe tripeptide; (g) Boc-P-ΔF-G-OMe tripeptide and (h) Curcumin-loaded Boc-P-ΔF-G-OMe tripeptide. (a and b: Reproduced from Reference (Mahato et al., 2012) with permission from the Royal Society of Chemistry; c and d: Reproduced from reference (Yadav et al., 2014a) with permission from the Royal Society of Chemistry; e and f: Reproduced from reference (Yadav et al., 2015) with permission from Bentham Science Publishers; g and h: Reproduced from reference (Deka et al., 2017) with permission from Elsevier.
List of peptide-based self-assembled nanostructures for drug delivery applications.
| Nanofibers | RAD16-II AcN-(RARADADA)2-CNH2 | IGF-1 (Myocardial infarction) | |
| Nanofibers coated with chitosan | Leucine-enkephalin NH2-Y(-O-palmitoyl)GGFL-OH | Enkephalin (Pain) | |
| Nanofibers coated with chitosan | NH2-Y(-O-palmitoyl) GGFLR-OH | Dalargin (Pain) | |
| Nanofibers | Palmitoyl-A4G3E3 | Camptothecin (Cancer) | |
| Nanofibers | Palmitoyl-V2A2E2K | Dexamethasone (Inflammation) | |
| Nanofibers | Palmitoyl-G3A4IKVAV | Spinal cord injury | |
| Nanofibers | Palmitoyl-(K)-V3E3SGGGYPVH PST-NH2 | Bone morphogenetic protein-2 (Spinal arthrodesis) | |
| Nanoparticles | Polylactide-V6K2(VVVVVVKK) | Doxorubicin, Paclitaxel (Cancer) | |
| Nanotubes | Lanreotide NH2-(D)Naph-CY(D)WKVCT-CONH2 | Acromegaly |
Self-assembled DNA nanostructures as drug delivery vectors.
| Tetrahedron | Doxorubicin (Cancer) | MDA-MB 468, MCF-7 cells | |
| Icosahedron 30 | Doxorubicin (Cancer) | Epithelial cancer cells | |
| Pyramidal nanostructure | Doxorubicin (Cancer) | MDA-MB-231, HepG2, LoVo LoVo-R | |
| Triangular prisms | Doxorubicin (Cancer) | MCF-7 breast cancer cells | |
| Crosslinked junctions | Doxorubicin (Cancer) | CCRF-CEM, Ramos, K562, K562/D | |
| Concatamers | Doxorubicin (Cancer) | Ramos, CEM cells, mouse model | |
| Nanoflowers | Doxorubicin (Cancer) | Ramos, CEM cells, mouse model, MCF-7, HeLa | |
| Cocoon | Doxorubicin (Cancer) | MCF-7 cells | |
| Triangular origami, Rectangular origami, Origami nanotubes | Doxorubicin (Cancer) | MCF-7, MDA-MB-231 cells | |
| Origami nanorods | Daunorubicin (Cancer) | HL-60 cells | |
| Origami nanoparticle superstructures | Doxorubicin (Cancer) | U87 cells |